A Phase 1b Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone or Apalutamide in mCRPC

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Masofaniten (Primary) ; Prednisolone (Primary) ; Prednisone (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ARES
Sponsors ESSA Pharma; Janssen Research & Development

05 Aug 2024 According to ESSA Pharma media release, the company plans to present the complete Phase 1b monotherapy results in the second half of 2024 at a medical conference.
08 May 2023 Status changed from suspended to discontinued.
12 Apr 2023 According to an ESSA Pharma media release, the company announces clinical trial support agreement with Janssen to evaluate EPI-7386 combinations in patients with prostate cancer, Under the terms of the Agreement, ESSA will sponsor and conduct this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com